000128929 001__ 128929
000128929 005__ 20240228143358.0
000128929 0247_ $$2doi$$a10.1007/s00280-016-2960-7
000128929 0247_ $$2pmid$$apmid:26793976
000128929 0247_ $$2ISSN$$a0344-5704
000128929 0247_ $$2ISSN$$a0943-9404
000128929 0247_ $$2ISSN$$a1432-0843
000128929 0247_ $$2altmetric$$aaltmetric:5023700
000128929 037__ $$aDKFZ-2017-04941
000128929 041__ $$aeng
000128929 082__ $$a610
000128929 1001_ $$aKönig, Miriam$$b0
000128929 245__ $$aInvestigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
000128929 260__ $$aBerlin$$bSpringer62507$$c2016
000128929 3367_ $$2DRIVER$$aarticle
000128929 3367_ $$2DataCite$$aOutput Types/Journal article
000128929 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522135660_18537
000128929 3367_ $$2BibTeX$$aARTICLE
000128929 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128929 3367_ $$00$$2EndNote$$aJournal Article
000128929 520__ $$aArtesunate (ART) has been used for a long time in the treatment of Plasmodium falciparum malaria and has been considered safe. The present phase I study aimed to determine the daily dose of ART that is well tolerated as add-on therapy in patients with breast cancer for 4 weeks of therapy. Ototoxicity could be a potential safety concern in settings different from malaria. Therefore, comprehensive audiological assessment was essential.The ARTIC M33/2 study was a prospective, open, uncontrolled, monocentric phase I dose-escalation study to evaluate the safety and tolerability of ART in patients with advanced breast cancer. Patients received either 100, 150 or 200 mg oral ART daily for a test phase of 4 weeks as add-on therapy to their ongoing oncological treatment. For the investigation of the safety of ART for hearing, an audiological assessment was performed with each patient before the intake of ART and after 4 weeks of therapy.Twenty-three female patients were included in the study. During the test phase, four patients had adverse events (AEs) of the auditory system possibly related to the intake of ART. However, none of these AEs was classified as severe AE (SAE) and did not require treatment interruption. Four patients had AEs concerning the vestibular system (vertigo) during the test phase, one of which was classified as SAE. However, the SAE was fully reversible after discontinuation of ART.None of the audiological results after 4 weeks of therapy with ART showed any dose-limiting auditory toxicity. However, audiological monitoring in further clinical studies with prolonged use of oral ART in doses up to 200 mg daily is warranted. The ARTIC M33/2 study is registered at eudract.ema.europa.eu with the Number 2007-004432-23 and at clinicaltrials.gov with the Number NCT00764036.
000128929 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128929 542__ $$2Crossref$$i2016-01-21$$uhttp://www.springer.com/tdm
000128929 588__ $$aDataset connected to CrossRef, PubMed,
000128929 650_7 $$2NLM Chemicals$$aAntimalarials
000128929 650_7 $$2NLM Chemicals$$aArtemisinins
000128929 650_7 $$060W3249T9M$$2NLM Chemicals$$aartesunate
000128929 7001_ $$avon Hagens, Cornelia$$b1
000128929 7001_ $$aHoth, Sebastian$$b2
000128929 7001_ $$aBaumann, Ingo$$b3
000128929 7001_ $$aWalter-Sack, Ingeborg$$b4
000128929 7001_ $$0P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aEdler, Lutz$$b5$$udkfz
000128929 7001_ $$aSertel, Serkan$$b6
000128929 77318 $$2Crossref$$3journal-article$$a10.1007/s00280-016-2960-7$$bSpringer Science and Business Media LLC$$d2016-01-21$$n2$$p413-427$$tCancer Chemotherapy and Pharmacology$$v77$$x0344-5704$$y2016
000128929 773__ $$0PERI:(DE-600)1458488-8$$a10.1007/s00280-016-2960-7$$gVol. 77, no. 2, p. 413 - 427$$n2$$p413-427$$tCancer chemotherapy and pharmacology$$v77$$x0344-5704$$y2016
000128929 909CO $$ooai:inrepo02.dkfz.de:128929$$pVDB
000128929 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128929 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128929 9141_ $$y2016
000128929 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128929 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128929 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128929 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128929 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128929 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CHEMOTH PHARM : 2015
000128929 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128929 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128929 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128929 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128929 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128929 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128929 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128929 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128929 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128929 980__ $$ajournal
000128929 980__ $$aVDB
000128929 980__ $$aI:(DE-He78)C060-20160331
000128929 980__ $$aUNRESTRICTED
000128929 999C5 $$1TM Davis$$2Crossref$$9-- missing cx lookup --$$a10.5694/j.1326-5377.2005.tb06650.x$$p181 -$$tMed J Aust$$uDavis TM, Karunajeewa HA, Ilett KF (2005) Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust 182(4):181–185$$v182$$y2005
000128929 999C5 $$1World Health Organization$$2Crossref$$tGuidelines for the treatment of malaria$$uWorld Health Organization (2006) Guidelines for the treatment of malaria. World Health Organization, Geneva$$y2006
000128929 999C5 $$1WC Sun$$2Crossref$$uSun WC, Han JX, Yang WY, Deng DA, Yue XF (1992) Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Zhongguo Yao Li Xue Bao 13(6):541–543$$y1992
000128929 999C5 $$1T Efferth$$2Crossref$$uEfferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18(4):767–773$$y2001
000128929 999C5 $$1Y Li$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0960-894X(00)00578-3$$p5 -$$tBioorg Med Chem Lett$$uLi Y, Shan F, Wu JM, Wu GS, Ding J, Xiao D, Yang WY, Atassi G, Leonce S, Caignard DH, Renard P (2001) Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett 11(1):5–8$$v11$$y2001
000128929 999C5 $$1NP Singh$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0024-3205(01)01372-8$$p49 -$$tLife Sci$$uSingh NP, Lai H (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70(1):49–56$$v70$$y2001
000128929 999C5 $$1P Reungpatthanaphong$$2Crossref$$9-- missing cx lookup --$$a10.1248/bpb.25.1555$$p1555 -$$tBiol Pharm Bull$$uReungpatthanaphong P, Mankhetkorn S (2002) Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25(12):1555–1561$$v25$$y2002
000128929 999C5 $$1GL Disbrow$$2Crossref$$9-- missing cx lookup --$$a10.1158/0008-5472.CAN-05-1216$$p10854 -$$tCancer Res$$uDisbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, Hartmann D, Schlegel R (2005) Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 65(23):10854–10861. doi: 10.1158/0008-5472.CAN-05-1216$$v65$$y2005
000128929 999C5 $$1HH Chen$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00280-003-0751-4$$p423 -$$tCancer Chemother Pharmacol$$uChen HH, Zhou HJ, Wang WQ, Wu GD (2004) Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 53(5):423–432. doi: 10.1007/s00280-003-0751-4$$v53$$y2004
000128929 999C5 $$1R Dell’Eva$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.bcp.2004.08.021$$p2359 -$$tBiochem Pharmacol$$uDell’Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T (2004) Inhibition of angiogenesis in vivo and growth of Kaposi’s sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 68(12):2359–2366. doi: 10.1016/j.bcp.2004.08.021$$v68$$y2004
000128929 999C5 $$1JC Moore$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0304-3835(06)80014-5$$p83 -$$tCancer Lett$$uMoore JC, Lai H, Li JR, Ren RL, McDougall JA, Singh NP, Chou CK (1995) Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 98(1):83–87$$v98$$y1995
000128929 999C5 $$1TG Berger$$2Crossref$$uBerger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G (2005) Artesunate in the treatment of metastatic uveal melanoma–first experiences. Oncol Rep 14(6):1599–1603$$y2005
000128929 999C5 $$1NP Singh$$2Crossref$$9-- missing cx lookup --$$a10.2298/AOO0204279S$$p279 -$$tArch Oncol$$uSingh NP, Verma KB (2002) Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol 10(4):279–280$$v10$$y2002
000128929 999C5 $$1RF Genovese$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0091-3057(00)00309-9$$p37 -$$tPharmacol Biochem Behav$$uGenovese RF, Newman DB, Brewer TG (2000) Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol Biochem Behav 67(1):37–44$$v67$$y2000
000128929 999C5 $$1RF Genovese$$2Crossref$$9-- missing cx lookup --$$a10.1016/S0361-9230(97)00339-0$$p199 -$$tBrain Res Bull$$uGenovese RF, Newman DB, Li Q, Peggins JO, Brewer TG (1998) Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull 45(2):199–202$$v45$$y1998
000128929 999C5 $$1E Kissinger$$2Crossref$$9-- missing cx lookup --$$a10.4269/ajtmh.2000.63.48$$p48 -$$tAm J Trop Med Hyg$$uKissinger E, Hien TT, Hung NT, Nam ND, Tuyen NL, Dinh BV, Mann C, Phu NH, Loc PP, Simpson JA, White NJ, Farrar JJ (2000) Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am J Trop Med Hyg 63(1–2):48–55$$v63$$y2000
000128929 999C5 $$1M Vugt Van$$2Crossref$$9-- missing cx lookup --$$a10.4269/ajtmh.2000.62.65$$p65 -$$tAm J Trop Med Hyg$$uVan Vugt M, Angus BJ, Price RN, Mann C, Simpson JA, Poletto C, Htoo SE, Looareesuwan S, White NJ, Nosten F (2000) A case–control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 62(1):65–69$$v62$$y2000
000128929 999C5 $$1MB McCall$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.trstmh.2006.02.017$$p1098 -$$tTrans R Soc Trop Med Hyg$$uMcCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, Sauerwein RW (2006) No hearing loss associated with the use of artemether–lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg 100(12):1098–1104. doi: 10.1016/j.trstmh.2006.02.017$$v100$$y2006
000128929 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.trstmh.2003.11.001$$uToovey S, Jamieson A (2004) Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 98(5):261–267; discussion 268-269. doi: 10.1016/j.trstmh.2003.11.001
000128929 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.trstmh.2004.11.006$$uMehta U, Barnes KI, Kathard H, Vugt M, Durrheim D (2005) Comment on: audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 99(4):313–314; author reply 314-315. doi: 10.1016/j.trstmh.2004.11.006
000128929 999C5 $$1R Hutagalung$$2Crossref$$9-- missing cx lookup --$$a10.4269/ajtmh.2006.74.211$$p211 -$$tAm J Trop Med Hyg$$uHutagalung R, Htoo H, Nwee P, Arunkamomkiri J, Zwang J, Carrara VI, Ashley E, Singhasivanon P, White NJ, Nosten F (2006) A case–control auditory evaluation of patients treated with artemether–lumefantrine. Am J Trop Med Hyg 74(2):211–214$$v74$$y2006
000128929 999C5 $$2Crossref$$9-- missing cx lookup --$$a10.1016/j.trstmh.2004.11.008$$uReinhart H, Hughson C, de Palacios PI (2005) Comment on: audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans R Soc Trop Med Hyg 99(4):315–316; author reply 316-317. doi: 10.1016/j.trstmh.2004.11.008
000128929 999C5 $$1LA Panossian$$2Crossref$$9-- missing cx lookup --$$a10.1002/ana.20620$$p812 -$$tAnn Neurol$$uPanossian LA, Garga NI, Pelletier D (2005) Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann Neurol 58(5):812–813. doi: 10.1002/ana.20620$$v58$$y2005
000128929 999C5 $$1NK Aaronson$$2Crossref$$9-- missing cx lookup --$$a10.1093/jnci/85.5.365$$p365 -$$tJ Natl Cancer I$$uAaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Dehaes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European-Organization-for-Research-and-Treatment-of-Cancer Qlq-C30—a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer I 85(5):365–376. doi: 10.1093/jnci/85.5.365$$v85$$y1993
000128929 999C5 $$1S Sertel$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.cbi.2010.02.002$$p42 -$$tChem Biol Interact$$uSertel S, Eichhorn T, Sieber S, Sauer A, Weiss J, Plinkert PK, Efferth T (2010) Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem Biol Interact 185(1):42–52. doi: 10.1016/j.cbi.2010.02.002$$v185$$y2010
000128929 999C5 $$1S Sertel$$2Crossref$$9-- missing cx lookup --$$a10.3390/molecules15042886$$p2886 -$$tMolecules$$uSertel S, Eichhorn T, Simon CH, Plinkert PK, Johnson SW, Efferth T (2010) Pharmacogenomic identification of c-Myc/Max-regulated genes associated with cytotoxicity of artesunate towards human colon, ovarian and lung cancer cell lines. Molecules 15(4):2886–2910. doi: 10.3390/molecules15042886$$v15$$y2010
000128929 999C5 $$1S Krishna$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.tips.2008.07.004$$p520 -$$tTrends Pharmacol Sci$$uKrishna S, Bustamante L, Haynes RK, Staines HM (2008) Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 29(10):520–527. doi: 10.1016/j.tips.2008.07.004$$v29$$y2008
000128929 999C5 $$1GL Firestone$$2Crossref$$9-- missing cx lookup --$$a10.1017/S1462399409001239$$pe32 -$$tExpert Rev Mol Med$$uFirestone GL, Sundar SN (2009) Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11:e32. doi: 10.1017/S1462399409001239$$v11$$y2009
000128929 999C5 $$1S Krishna$$2Crossref$$9-- missing cx lookup --$$a10.1016/j.ebiom.2014.11.010$$p82 -$$tEBioMedicine$$uKrishna S, Ganapathi S, Ster IC, Saeed ME, Cowan M, Finlayson C, Kovacsevics H, Jansen H, Kremsner PG, Efferth T, Kumar D (2015) A randomised, double blind, placebo-controlled pilot study of oral artesunate therapy for colorectal cancer. EBioMedicine 2(1):82–90. doi: 10.1016/j.ebiom.2014.11.010$$v2$$y2015
000128929 999C5 $$1G Carrasquilla$$2Crossref$$9-- missing cx lookup --$$a10.4269/ajtmh.2012.11-0192$$p75 -$$tAm J Trop Med Hyg$$uCarrasquilla G, Baron C, Monsell EM, Cousin M, Walter V, Lefevre G, Sander O, Fisher LM (2012) Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether–lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 86(1):75–83. doi: 10.4269/ajtmh.2012.11-0192$$v86$$y2012
000128929 999C5 $$1VI Carrara$$2Crossref$$9-- missing cx lookup --$$a10.1186/1475-2875-7-233$$p233 -$$tMalar J$$uCarrara VI, Phyo AP, Nwee P, Soe M, Htoo H, Arunkamomkiri J, Singhasivanon P, Nosten F (2008) Auditory assessment of patients with acute uncomplicated Plasmodium falciparum malaria treated with three-day mefloquine-artesunate on the north-western border of Thailand. Malar J 7:233. doi: 10.1186/1475-2875-7-233$$v7$$y2008
000128929 999C5 $$1R Gurkov$$2Crossref$$9-- missing cx lookup --$$a10.1186/1475-2875-7-179$$p179 -$$tMalar J$$uGurkov R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M, Hempel JM, Loscher T (2008) Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J 7:179. doi: 10.1186/1475-2875-7-179$$v7$$y2008
000128929 999C5 $$1J Schmutzhard$$2Crossref$$9-- missing cx lookup --$$a10.1186/1475-2875-9-159$$p159 -$$tMalar J$$uSchmutzhard J, Kositz CH, Lackner P, Dietmann A, Fischer M, Glueckert R, Reindl M, Stephan K, Riechelmann H, Schrott-Fischer A, Schmutzhard E (2010) Murine malaria is associated with significant hearing impairment. Malar J 9:159. doi: 10.1186/1475-2875-9-159$$v9$$y2010
000128929 999C5 $$1GO Adjei$$2Crossref$$9-- missing cx lookup --$$a10.1155/2013/360540$$p360540 -$$tJ Trop Med$$uAdjei GO, Goka BQ, Kitcher E, Rodrigues OP, Badoe E, Kurtzhals JA (2013) Reversible audiometric threshold changes in children with uncomplicated malaria. J Trop Med 2013:360540. doi: 10.1155/2013/360540$$v2013$$y2013